

## *Dr. Thomas Schreitmueller*



Thomas Schreitmueller holds a Diploma and PhD in Biochemistry from the University of Munich (Max Planck Institute for Biochemistry, Munich, Martinsried and Institute for Clinical Chemistry and Clinical Biochemistry University of Munich).

In 1989 he joined Roche holding various positions in the biotech area (e.g. Analytical R&D, technical project management).

Since 2003 Thomas was heading the department "Analytical R&D and Quality Control Biotech Products" at Roche Pharma Technical Operations in Basel, Switzerland.

As off 2010 Thomas was the global lead for international regulatory policy for biologics within Roche's regulatory policy group at Roche Pharma Technical Operations leading and coordinating the development of Roche positions on regulatory policy topics related to biotheapeutic and similar biotherapeutic products.

Since 2015 Thomas is head of regulatory policy group at Roche Pharma Technical Operations leading and co-ordinating Roche's regulatory policy activities.

### Health-/Industry-Organisation Engagement

1989-present Roche representation in various WHO-, ICH-, IFPMA-, EFPIA-, EBE-, FIFARMA, BIO-biotech working groups.

Currently member of:

Different BIO Working groups; <http://www.bio.org/>  
EBE - Regulatory & Technical Affairs Committee; <http://www.ebe-biopharma.eu/>  
EFPIA – Growth Markets; <http://www.efpia.eu/>  
IFPMA Biotherapeutic Working Group; <http://www.ifpma.org/>  
FIFARMA Member of the Advisory Board and Co-Chair of the Biotherapeutic/Regulatory Working Group; <http://www.fifarma.org/>

Member of the CASSS "CMC Forum Global Steering Committee" and the Organizing Committees of the "CMC Strategy Forum Europe" and "CMC Strategy Forum LATAM"  
<http://www.casss.org/>